Periplocin, a cardiac glycoside, was found to inhibit NRF2 expression and its downstream signaling in gemcitabine-resistant pancreatic cancer cells, and thus significantly inhibited cell growth in vitro and in vivo [155]. This evidence concerns the gene NFE2L2 and familial pancreatic carcinoma.